Special Issue "Advances in Diagnosis and Management of Malignant Pleural Mesothelioma and Malignant Pleural Effusion: Novel Insights in Local and Cell Therapies"

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 137

Special Issue Editors

Department of Medical Sciences and Infectious Diseases, Unit of Respiratory System Diseases, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy
Interests: cancer; metastases; mesothelioma; targeted therapies; genetics
Special Issues, Collections and Topics in MDPI journals
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80145 Naples, Italy
Interests: COVID-19; interstitial lung diseases; metabolic dysfuntion in chronic respiratory disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant mesothelioma is a rare tumor arising from the mesothelial cells lining the pleura, pericardium, peritoneum, and tunica vaginalis. Malignant pleural mesothelioma (MPM) is the most common pleural tumour closely related to chronic asbestos inhalation with a median overall survival around 12 months. However, recent advances in understanding the mechanisms involved in cancerogenesis as well the complex network between cancer cells and immune innate response have led to significant advances in the therapeutic scenario of MPM. In this collection, we aim to include research focused on molecular and biological mechanisms of MPM, potential biomarkers, and diagnostic technique advancements for diagnosing and monitoring MPM, innovative (local and cell) therapies for MPM, and the management of comorbid conditions (e.g., malignant pleural effusion) which may contribute to the burden of the disease.

Dr. Giulia M. Stella
Dr. Fabio Perrotta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • malignant pleural mesothelioma
  • asbestos-induced lung disease
  • immunotherapy
  • pleural disease
  • biomarkers
  • cell therapy
  • malignant pleural effusion
  • multimodal therapy
  • nivolumab
  • ipilimumab

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop